Review new trial data showing how targeted lipid therapies affect pancreatitis risk and cardiovascular outcomes in people with high-risk diabetes.
Key Takeaways
- Two phase 3 trials enrolled 1,063 patients including 673 with diabetes
- Olezarsen reduced triglycerides by 57.4% and 64.8% in patients with diabetes
- Evolocumab lowered LDL-C over 50% and reduced cardiovascular events in high-risk diabetes